Guangzhou Boji Medical and Biotechnological Co Ltd (300404) - Cash Flow Conversion Efficiency

Latest as of June 2023: -0.008x

Based on the latest financial reports, Guangzhou Boji Medical and Biotechnological Co Ltd (300404) has a cash flow conversion efficiency ratio of -0.008x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-7.39 Million ≈ $-1.08 Million USD) by net assets (CN¥918.92 Million ≈ $134.47 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Guangzhou Boji Medical and Biotechnologi (300404) total market value for the company's overall valuation and market capitalisation.

Guangzhou Boji Medical and Biotechnological Co Ltd - Cash Flow Conversion Efficiency Trend (2012–2025)

This chart illustrates how Guangzhou Boji Medical and Biotechnological Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Guangzhou Boji Medical and Biotechnological Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Guangzhou Boji Medical and Biotechnological Co Ltd ranked by their cash flow conversion efficiency. Explore earnings quality score of Guangzhou Boji Medical and Biotechnologi to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
JDM Jingda Mach(Ningbo)Co Ltd
SHG:603088
0.077x
AnShan Heavy Duty Mining Machinery Co Ltd
SHE:002667
0.106x
Yext Inc
NYSE:YEXT
0.055x
Cybrid Technologies Inc
SHG:603212
0.041x
D-MARKET Electronic Services & Trading ADR
NASDAQ:HEPS
0.043x
Pakuwon Jati Tbk
JK:PWON
0.026x
LOGAN GROUP HD -10
F:5LP
N/A
Companhia de Saneamento do Paraná - SANEPAR
SA:SAPR3
0.045x

Annual Cash Flow Conversion Efficiency for Guangzhou Boji Medical and Biotechnological Co Ltd (2012–2025)

The table below shows the annual cash flow conversion efficiency of Guangzhou Boji Medical and Biotechnological Co Ltd from 2012 to 2025. View 300404 stock price for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 CN¥1.06 Billion
≈ $155.04 Million
CN¥87.01 Million
≈ $12.73 Million
0.082x +207.18%
2024-12-31 CN¥1.00 Billion
≈ $146.59 Million
CN¥26.78 Million
≈ $3.92 Million
0.027x -27.12%
2023-12-31 CN¥980.11 Million
≈ $143.42 Million
CN¥35.95 Million
≈ $5.26 Million
0.037x +15.86%
2022-12-31 CN¥888.72 Million
≈ $130.05 Million
CN¥28.14 Million
≈ $4.12 Million
0.032x -10.97%
2021-12-31 CN¥846.38 Million
≈ $123.85 Million
CN¥30.10 Million
≈ $4.40 Million
0.036x -82.23%
2020-12-31 CN¥485.00 Million
≈ $70.97 Million
CN¥97.07 Million
≈ $14.20 Million
0.200x +106199.25%
2019-12-31 CN¥456.08 Million
≈ $66.74 Million
CN¥85.87K
≈ $12.57K
0.000x -99.71%
2018-12-31 CN¥423.71 Million
≈ $62.00 Million
CN¥27.06 Million
≈ $3.96 Million
0.064x +0.92%
2017-12-31 CN¥414.35 Million
≈ $60.63 Million
CN¥26.22 Million
≈ $3.84 Million
0.063x +179.45%
2016-12-31 CN¥429.84 Million
≈ $62.90 Million
CN¥-34.24 Million
≈ $-5.01 Million
-0.080x -1889.41%
2015-12-31 CN¥432.68 Million
≈ $63.32 Million
CN¥1.93 Million
≈ $281.83K
0.004x -96.21%
2014-12-31 CN¥218.48 Million
≈ $31.97 Million
CN¥25.69 Million
≈ $3.76 Million
0.118x -44.43%
2013-12-31 CN¥205.52 Million
≈ $30.07 Million
CN¥43.48 Million
≈ $6.36 Million
0.212x -12.94%
2012-12-31 CN¥170.36 Million
≈ $24.93 Million
CN¥41.40 Million
≈ $6.06 Million
0.243x --

About Guangzhou Boji Medical and Biotechnological Co Ltd

SHE:300404 China Biotechnology
Market Cap
$756.39 Million
CN¥5.17 Billion CNY
Market Cap Rank
#10265 Global
#2745 in China
Share Price
CN¥13.40
Change (1 day)
+2.06%
52-Week Range
CN¥8.29 - CN¥17.60
All Time High
CN¥297.35
About

Boji Medical Technology Co.,Ltd. provides professional contract research services for research and development, and production of drugs and medical devices to pharmaceutical enterprises in China and internationally. The company offers pre-clinical research, clinical research, and other consulting services. It also provides clinical drug production, pilot test scale-up, process verification batch … Read more